Our Team

Seasoned management team of cytometric profiling experts, experienced clinicians, and biotech professionals.

Leadership, Research, and Collaboration

Cytometric Therapeutics is guided by a team of clinicians and scientists dedicated to advancing functional oncology from the laboratory to the clinic.

Larry Weisenthal

Larry Weisenthal, MD, PhD

Chief Science Officer
  • Clinical Associate, Medicine Branch, National Cancer Institute
  • Board Certified: Internal Medicine & Medical Oncology
  • Clinical Professor of Medicine (Hematology/Oncology), U. Cal Irvine School of Medicine
  • 30 years experience directing two California, Medicare, and CLIA licensed clinical oncology labs
  • MD, PhD (Pharmacology) U. Michigan School of Medicine
William Grace, MD

William Grace, MD

Chief Medical Officer
  • Research Associate, Experimental Hematology & Immunology, NIH Navy
  • Director, Armed Forces Bone Marrow Transplant Program
  • Chief of Cancer Research & Medical Oncology, St. Vincent’s
  • President, New York Cancer Society
  • 30 years Castle Connolly Top Doctor
  • Notre Dame, BS · Boston University, MD
Laurin Cristiano, MD

Laurin Cristiano, MD

VP of Research
  • Asst. Prof. of OB-GYN, Loma Linda Univ. School of Medicine
  • 4 years bench research in cell biology (stem cell) science
  • Former start-up biotech researcher, iPierian (acquired by Bristol-Myers Squibb for $750M)
  • Harvard, BA, Biochemistry
  • University of Colorado School of Medicine, MD
William Grace

William Grace

Chief Operating Officer
  • Co-Founder, COO MDRx Financial, the first comprehensive healthcare data network for financial markets
  • Co-Founder, COO Good Works Health, the first federal-government approved online marketing platform
  • BA, Dartmouth College
  • Chairman, Dartmouth Union
  • Editor-in-Chief, Dartmouth Review
Paul Kanan

Paul Kanan

Chief Executive Officer
  • EVP & CFO Agensys, acquired by Astellas in 2007
  • CEO of Pacific Biometrics: led company from start-up to successful IPO in 1996
  • CEO of Oncotech: joined with Larry Weisenthal in early development of assay assisted drug selection technology for cancer
  • Division President, Baxter Healthcare
  • BS Engineering, University of Michigan · MBA, Harvard
Nicola Caiano

Nicola Caiano

Chief Financial Officer
  • Founding Partner, Olea Management LLC
  • Partner – Director of Research, Pinyon Asset Management
  • Senior Analyst, Paulson & Co.
  • Partner, Amajac Capital Management LLC
  • Proprietary Positioning Business, J.P. Morgan Chase
  • NYU Stern School of Business, BS, Accounting and Finance
Scientific and advisory team
Scientific and Advisory Team

Cytometric Therapeutics collaborates with a network of scientists, data specialists, and clinical advisors who bring expertise in cytometry, drug discovery, and translational oncology. Their collective insight strengthens the company’s ability to move discoveries efficiently from the laboratory to patient-ready programs.

Careers at CTI

Join a team translating science into patient impact

Cytometric Therapeutics is building a collaborative environment where scientific rigor meets real-world application. Our work advances functional precision oncology through live-cell analysis, translational research, and measurable innovation. We bring together laboratory scientists, clinicians, and operational experts who share one mission: to turn data into discovery.

Research & Laboratory

  • Research Scientists and Laboratory Technicians
  • Cytometry and Assay Development
  • Translational Oncology Support

Data & Operations

  • Project Managers (Clinical and Translational)
  • Computational and Data Scientists
  • Technical and Administrative Operations
We value evidence, curiosity, and collaboration. Our culture encourages thoughtful science and shared responsibility for discovery.
Contact the CTI Team

If you are interested in future opportunities, contact our team or follow updates as positions become available.